In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device/Diagnostics Quarterly Dealmaking Statistics, Q2 2019

A Look At The Financing, M&A And Alliance Activity In April–June 2019

Executive Summary

Device financing totaled $2.3bn for Q2 2019, with the debt category bringing in the most money. Merger and acquisition deals reached an aggregate $9.1bn (a 25% increase from Q1), thanks mostly to 3M’s  $6.7bn takeover of Acelity and its KCI subsidiaries. Diagnostics/research financing, which totaled $2.4bn, showed a significant rise from the previous quarter, while diagnostics/research tools M&A values, at $233m, exhibited a steep decline.

You may also be interested in...



Perrigo Remains Committed To Splitting Off Prescription Despite Delay

Perrigo has pushed back plans to split off its Prescription business as part of its transformation into a consumer self-care focused company.

Acutus Completes $170M Financing To Support AcQMap Commercialization

The deal includes $100m in Series D financing and a $70m credit facility to help Acutus market the AcQMap electrophysiology mapping system along with the associated vascular access devices, AcQCross QX, AcQGuide Flex and AcQGuide Mini.

Medtronic And Boston Scientific Finance Saluda's Neuromodulation System

Saluda Medical has secured funds from Medtronic and Boston Scientific to support the development of its spinal cord stimulation system for pain management.

Related Content

Topics

Related Deals

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel